HMGB1 and metabolic syndrome: The use of anti-HMGB1 neutralizing antibody effectively reduce HFD-induced weight gain and liver inflammation in mice (Montes et al., 2015), suggesting that TLR4 is likely a key therapeutic target for dyslipidemia and obesity.